How to Get Testosterone Cypionate in Delaware

Delaware Prescribing Laws for Testosterone Cypionate

Delaware permits any appropriately licensed prescriber to write a testosterone cypionate prescription, including through telehealth platforms. The state does not impose a separate controlled substance telehealth restriction beyond federal DEA requirements for Schedule III drugs.

Testosterone cypionate is classified as a Schedule III controlled substance under both federal law and the Delaware Uniform Controlled Substances Act (Title 16, Chapter 47). This classification means prescribers must hold an active DEA registration and a Delaware Controlled Substance Registration (CSR). The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only after a confirmed diagnosis of hypogonadism, defined as total testosterone consistently below 300 ng/dL combined with symptoms such as fatigue, reduced libido, or loss of muscle mass.

Delaware's Board of Medical Licensure and Discipline updated its telehealth guidance in alignment with the Ryan Haight Act, which requires a valid prescriber-patient relationship before issuing a controlled substance prescription [1]. For telehealth consultations, this relationship can be established through a real-time audio-video encounter. A phone-only visit does not satisfy the requirement for an initial testosterone cypionate prescription in most circumstances.

The state also recognizes the Interstate Medical Licensure Compact, allowing physicians licensed through the Compact to practice telehealth in Delaware without a separate state license. This broadens access for patients in Sussex and Kent counties, where endocrinology specialists are scarce.

Who Can Prescribe: MD, NP, and PA Scope in Delaware

Three types of providers can prescribe testosterone cypionate in Delaware: physicians (MD/DO), nurse practitioners, and physician assistants. Each operates under different regulatory frameworks.

Physicians hold full independent prescriptive authority for Schedule III substances. Delaware nurse practitioners gained independent practice authority under Senate Bill 140 (2019), meaning NPs with prescriptive authority certification can diagnose hypogonadism and prescribe testosterone cypionate without physician oversight. This is a meaningful distinction for rural Delaware patients who may not have convenient access to an endocrinologist or urologist.

Physician assistants in Delaware must maintain a collaborative agreement with a supervising physician, though the physician does not need to co-sign every prescription. The PA's collaborative agreement must specifically authorize prescribing Schedule III controlled substances. PAs working in telehealth settings follow the same collaboration requirements as those in brick-and-mortar clinics.

Board certification in endocrinology is not required. Primary care providers, urologists, and men's health specialists all commonly manage testosterone replacement therapy (TRT). The American Urological Association's 2018 guideline supports this broad prescribing base, noting that "testosterone therapy should be offered to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function."

Required Lab Work Before Starting Treatment

You will need specific blood tests before any Delaware provider can prescribe testosterone cypionate. The minimum diagnostic workup includes two morning total testosterone measurements drawn before 10:00 a.m. on separate days.

Morning collection matters because testosterone follows a circadian rhythm, peaking between 6:00 a.m. and 9:00 a.m. and declining throughout the day. A single low reading is insufficient. The Endocrine Society guideline explicitly states: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations" [2]. Two confirmatory draws are the standard.

Beyond testosterone levels, a complete pre-treatment panel typically includes:

• Total and free testosterone (drawn fasting, before 10:00 a.m.)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit baseline, since testosterone therapy raises red blood cell production
• Comprehensive metabolic panel including liver function
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Prostate-specific antigen (PSA) for men over 40
• Prolactin if secondary hypogonadism is suspected

Quest Diagnostics and Labcorp both operate multiple draw sites across New Castle, Kent, and Sussex counties. Most telehealth TRT providers will order these labs electronically and send you to a local collection site. Results typically return within 2 to 4 business days.

The T-Trials, a coordinated set of seven placebo-controlled trials published in the New England Journal of Medicine, enrolled 790 men aged 65 and older with testosterone levels below 275 ng/dL. After 12 months of treatment with testosterone gel, participants showed statistically significant improvements in sexual function, physical activity, and mood compared to placebo [3]. These findings reinforced the clinical value of confirming low testosterone before initiating therapy, rather than prescribing based on symptoms alone.

The Telehealth Pathway: Step by Step

A Delaware resident can go from initial consultation to first injection in roughly 7 to 14 days using a telehealth provider. The process follows a predictable sequence.

Step 1: Choose a provider. Select a telehealth platform or individual provider licensed in Delaware with DEA registration for Schedule III prescribing. Verify that the provider offers synchronous video consultations, not just asynchronous messaging.

Step 2: Complete intake forms. Most platforms collect a symptom questionnaire (covering libido, energy, mood, body composition changes), medical history, current medications, and family history of prostate cancer or cardiovascular disease.

Step 3: Get labs drawn. The provider orders the lab panel described above. You visit a local draw site. Some providers accept recent labs (within 6 months) if they include two qualifying morning testosterone values.

Step 4: Video consultation. A licensed prescriber reviews your labs, symptoms, and medical history during a real-time video visit. If you meet diagnostic criteria (total testosterone below 300 ng/dL on two draws, plus symptoms), the provider discusses treatment options. The FDA-approved prescribing information for testosterone cypionate specifies the indication as replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone [4].

Step 5: Prescription and pharmacy selection. The provider sends the prescription electronically to your chosen pharmacy. Delaware law permits e-prescribing of Schedule III substances. You can select a retail chain pharmacy (CVS, Walgreens, Rite Aid) or a licensed 503A compounding pharmacy.

Step 6: Begin treatment. Standard dosing for testosterone cypionate ranges from 50 to 200 mg injected intramuscularly or subcutaneously once weekly or split into twice-weekly doses. The prescriber determines your specific protocol based on your lab values, body weight, and clinical response.

Pharmacy Options: Retail vs. 503A Compounding

Delaware patients can fill testosterone cypionate prescriptions at retail pharmacies or through licensed 503A compounding pharmacies. Each option has distinct advantages.

Retail pharmacies stock commercially manufactured testosterone cypionate in standard concentrations (typically 200 mg/mL in cottonseed oil or sesame oil). Generic testosterone cypionate at a retail pharmacy costs approximately $30 to $90 per month without insurance, depending on dose and pharmacy pricing. GoodRx and similar discount programs often bring the cash price to the lower end of that range.

503A compounding pharmacies in Delaware operate under state Board of Pharmacy oversight and can customize testosterone cypionate formulations. Compounded options include different carrier oils (grapeseed oil for patients with cottonseed allergy), adjusted concentrations, and combination formulations. The FDA's guidance on 503A compounding requires that compounded preparations be made in response to individual patient prescriptions [5].

Delaware-licensed 503A pharmacies may ship compounded testosterone cypionate directly to patients within the state. This is particularly valuable for residents in lower Delaware (Kent and Sussex counties) who live far from specialty pharmacies. Verify that any compounding pharmacy holds a current Delaware Board of Pharmacy license and compounds in compliance with USP 797 sterile compounding standards.

A key consideration: insurance plans typically cover commercially manufactured generic testosterone cypionate but will not reimburse compounded versions. If cost is a concern and you have insurance coverage, a retail pharmacy prescription for the commercial product is usually the most affordable path.

Insurance Coverage and Prior Authorization in Delaware

Delaware Medicaid covers testosterone cypionate for the diagnosis of male hypogonadism, but requires prior authorization (PA) before approving the claim. Private insurers in the state follow similar patterns.

The prior authorization process for Delaware Medicaid generally requires three pieces of documentation: (1) two laboratory-confirmed morning testosterone levels below 300 ng/dL, (2) a documented clinical diagnosis of hypogonadism with ICD-10 code E29.1, and (3) evidence that the patient has signs or symptoms attributable to testosterone deficiency. Some plans also require documentation that secondary causes of low testosterone (such as opioid use, pituitary disorders, or obesity) have been evaluated or addressed.

For commercial insurance through employers or ACA marketplace plans, coverage rules vary by carrier. Most Delaware commercial plans (Highmark, Aetna, Cigna) list generic testosterone cypionate on their formulary at a Tier 2 or Tier 3 level. Copays typically range from $10 to $45 per month with insurance. The American Association of Clinical Endocrinology (AACE) guideline supports testosterone therapy in men with confirmed hypogonadism and notes that "the benefits of testosterone therapy in appropriately selected men include improvements in sexual function, bone mineral density, body composition, and sense of well-being" [6].

If your prior authorization is denied, Delaware insurance regulations grant you the right to appeal. The appeal should include your full lab history, a letter of medical necessity from your prescriber, and supporting guideline citations. Most PA approvals or denials are processed within 72 hours for standard requests, or 24 hours for urgent requests under Delaware Medicaid rules.

Dosing Protocols and Self-Injection Guidance

Testosterone cypionate is administered via intramuscular (IM) or subcutaneous (SubQ) injection, with most protocols calling for weekly or twice-weekly dosing. Your prescriber sets the specific dose based on your baseline testosterone, treatment goals, and follow-up lab results.

The standard starting dose is 100 mg per week for most men with primary or secondary hypogonadism. Some providers start at 150 to 200 mg weekly for men with very low baseline values (below 200 ng/dL), while others prefer a conservative 75 to 100 mg starting point and titrate upward based on follow-up labs at 8 to 12 weeks. Twice-weekly dosing (splitting the weekly dose into two injections) produces more stable serum levels and may reduce side effects related to peak-and-trough fluctuations [7].

For IM injection, the recommended sites are the vastus lateralis (outer thigh) and the ventrogluteal (upper outer buttock). A 22 to 25 gauge needle, 1 to 1.5 inches in length, is standard. SubQ injection uses a smaller needle (25 to 30 gauge, 0.5 inch) and targets the abdominal fat pad or upper thigh fat. A 2014 study published in the Journal of Clinical Endocrinology & Metabolism found that subcutaneous testosterone cypionate achieved comparable serum levels to intramuscular injection with potentially fewer injection-site reactions [8].

Self-injection is the norm for testosterone cypionate. Your provider or a clinical staff member should walk you through the injection technique during your initial visit or via video demonstration. Key steps include proper hand hygiene, drawing the correct volume from the vial, removing air bubbles, selecting and rotating injection sites, and safe sharps disposal. Delaware law requires that used needles be placed in an FDA-cleared sharps container or a heavy-duty plastic container (such as a laundry detergent bottle) before disposal in household trash.

Monitoring and Follow-Up Requirements

Ongoing monitoring is not optional. It is a clinical requirement. Your prescriber should order follow-up labs at 3 months, 6 months, and then every 6 to 12 months while you remain on testosterone cypionate.

The monitoring panel includes total testosterone (drawn midway between injections to capture trough levels), CBC with hematocrit, PSA (for men over 40), and a metabolic panel. Hematocrit monitoring is especially important because testosterone stimulates erythropoiesis. The Endocrine Society guideline recommends reducing the testosterone dose or holding therapy if hematocrit exceeds 54%, due to the increased risk of thromboembolic events [2].

A 2019 meta-analysis published in JAMA Internal Medicine, pooling data from 35 randomized controlled trials involving over 5,500 men, found that testosterone therapy was associated with an increased risk of polycythemia (hematocrit >54%) with a number needed to harm of approximately 14 over 12 months of treatment [9]. This reinforces the need for consistent hematocrit surveillance, not just at baseline.

Target trough testosterone levels on therapy generally fall between 400 and 700 ng/dL. If your trough is below 400 ng/dL with persistent symptoms, your provider may increase the dose. If trough values exceed 700 to 800 ng/dL or side effects emerge (acne, mood changes, elevated hematocrit), a dose reduction is appropriate. Estradiol levels should be checked if symptoms of estrogen excess (gynecomastia, water retention) appear, though routine estradiol monitoring in asymptomatic men is debated.

Risks, Contraindications, and Safety Considerations

Testosterone cypionate carries specific risks and absolute contraindications that Delaware prescribers must evaluate before initiating therapy.

Absolute contraindications include known or suspected prostate cancer, male breast cancer, untreated severe obstructive sleep apnea, uncontrolled heart failure, and a desire for near-term fertility (testosterone suppresses spermatogenesis). The FDA label for testosterone cypionate includes a warning about potential cardiovascular risk, and the agency required a class-wide label change for all testosterone products in 2015 [4].

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provided the most definitive cardiovascular safety data to date. This randomized, double-blind, placebo-controlled trial enrolled 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease. At a mean follow-up of 33 months, testosterone treatment did not result in a significantly higher incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.96; 95% CI, 0.78 to 1.17) [10]. Dr. Shalender Bhasin, the study's principal investigator, stated: "These findings should provide reassurance to clinicians and patients that testosterone therapy, when prescribed for appropriate indications, does not increase the risk of major cardiovascular events" [10].

Common side effects include acne (reported in approximately 20% of patients), injection-site soreness, increased hematocrit, and mild fluid retention. Less common effects include gynecomastia, mood changes, and testicular atrophy from suppressed gonadotropin secretion. Fertility suppression is expected during therapy and typically reverses within 6 to 12 months after discontinuation, though recovery time varies.

Delaware-Specific Access Considerations

Delaware's small geographic size and limited specialist density create both advantages and barriers for TRT access. The state has roughly 1 million residents across three counties, with the majority of endocrinologists and urologists concentrated in New Castle County (Wilmington area).

For residents in Dover, Georgetown, and other downstate areas, telehealth removes the need for a 60 to 90 minute drive to see a specialist. Delaware's lack of restrictive telehealth prescribing laws for Schedule III substances makes the state one of the more accessible East Coast markets for online TRT. Patients in the Delmarva region can also access providers licensed in Maryland or Pennsylvania through interstate telehealth compacts, though the prescription must still be filled at a pharmacy licensed in the state where the patient is located.

Delaware does not impose a state-level prescription drug monitoring program (PDMP) query mandate specific to testosterone, but providers are encouraged to check the Delaware PDMP (operated through the Board of Pharmacy) before prescribing any controlled substance. This helps identify patients who may be obtaining testosterone from multiple providers.